Nanobiotix’s (NBTX) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Nanobiotix (NASDAQ:NBTX) in a research note published on Friday morning, Zacks.com reports.

Nanobiotix Price Performance

NASDAQ NBTX opened at $5.81 on Friday. The business’s 50 day moving average price is $6.26 and its 200-day moving average price is $6.54. Nanobiotix has a fifty-two week low of $1.75 and a fifty-two week high of $11.00.

Institutional Investors Weigh In On Nanobiotix

An institutional investor recently raised its position in Nanobiotix stock. Baillie Gifford & Co. boosted its position in Nanobiotix S.A. (NASDAQ:NBTX) by 48.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 2,869,030 shares of the company’s stock after purchasing an additional 932,835 shares during the period. Baillie Gifford & Co. owned approximately 6.09% of Nanobiotix worth $20,887,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 38.81% of the company’s stock.

About Nanobiotix

Nanobiotix SA, a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer.